SRR11296733
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- MYC_TARGETS_V1+0.490
- G2M_CHECKPOINT+0.440
- PROTEIN_SECRETION+0.310
- SPERMATOGENESIS+0.290
- GLYCOLYSIS+0.270
- INTERFERON_ALPHA_RESPONSE+0.270
- MTORC1_SIGNALING+0.270
- OXIDATIVE_PHOSPHORYLATION+0.230
- PANCREAS_BETA_CELLS+0.230
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- MYOGENESIS-0.440
- WNT_BETA_CATENIN_SIGNALING-0.440
- ANGIOGENESIS-0.400
- HEDGEHOG_SIGNALING-0.390
- TGF_BETA_SIGNALING-0.360
- APICAL_JUNCTION-0.350
- NOTCH_SIGNALING-0.340
- UV_RESPONSE_DN-0.300
- COAGULATION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 48507_S107 | — | cohortMD1 | 0.889 |
| 2 | R135 | — | — | 0.885 |
| 3 | SRR11296797 | — | — | 0.868 |
| 4 | SRR8518395 | — | E | 0.854 |
| 5 | TCGA-XF-AAML-01A-11R-A42T-07 | — | — | 0.850 |
| 6 | TCGA-C8-A12U-01A-11R-A115-07 | — | B | 0.845 |
| 7 | SRR27320678 | — | — | 0.842 |
| 8 | d01f4531-b145-414b-bc1c-0f1a148b771e | — | — | 0.838 |
| 9 | SRR1797282 | — | cohortSC | 0.838 |
| 10 | s0102864 | — | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.090 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.050 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |